| Our data disclose a hitherto unexplored link between the putative oncogene EZH2 and the tumor suppressor PSP94, and show that MSMB is silenced by EZH2 in advanced prostate cancer cells. | prostate, |
| ADRB2 inhibition confers cell invasion and transforms benign prostate epithelial cells, whereas ADRB2 overexpression counteracts EZH2-mediated oncogenesis | prostate, |
| An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. | prostate, |
| Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. | lung, |
| EZH2 gene acts as an oncogene in tumorigenesis of ovarian cancer with the possible mechanism to suppress the anti-oncogene p57. | ovarian, |
| RAS oncogenic signal upregulates EZH2 in pancreatic cancer. | pancreatic, |
| MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. | lung, |
| the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor. Instead, it involves the ability of EZH2 to act as a coactivator for critical transcription factors including the androgen receptor. | prostate, |
| EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. | prostate, |
| Our study uncovers an oncogenic role of EZH2 independent of its methyltransferase activity in natural killer T-cell lymphoma. | lymphoma, |
| FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. | nasopharyngeal,laryngeal, |
| Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer. | lung, |
| Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer. | lung, |
| The histone methyltransferase EZH2, an oncogene common to benign and malignant parathyroid tumors. | thyroid, |
| EZH2 acts as an oncogene and plays an important role in oral squamous cell carcinoma metastasis and inhibition of apoptosis. | oral |
| Role of EZH2 in oral squamous cell carcinoma carcinogenesis. | oral |
| EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. | glioblastoma, |
| Results suggest that the testicular nuclear receptor 4 (TR4) and oncogene EZH2 signaling may play a critical role in the prostate cancer stem/progenitor cell invasion. | testicular,prostate, |
| demonstrated that EZH2 plays a crucial role in tumor growth and distant metastasis in osteosarcoma; its oncogenic role is related to its regulation of the expression of TSSC3 | osteosarcoma, |
| EZH2 serves as an oncogene and is involved in multiple glioma cell processes, including cell cycle, invasion, glioma stem cell maintenance, drug and radiotherapy resistance. | glioma, |